InvestorsHub Logo
Followers 618
Posts 27445
Boards Moderated 3
Alias Born 11/16/2007

Re: Jhawker post# 186886

Thursday, 06/22/2017 6:08:16 PM

Thursday, June 22, 2017 6:08:16 PM

Post# of 402459
For those that haven't seen today's poster:

https://learningcenter.ehaweb.org/eha/2017/22nd/180680/roberta.napolitano.kevetrin.preclinical.study.of.a.new.compound.in.acute.html

KEVETRIN: PRECLINICAL STUDY OF A NEW COMPOUND IN ACUTE MYELOID LEUKEMIA

Conclusion
Our results suggest Kevetrin is a promising new drug in AML patients treatment, both in wild type and, even more, in TP53 mutated tumors, through different molecular mechanisms, giving more therapeutic alternatives in the treatment of this disease.


However, I'm more interested in seeing trial results this year from the kevetrin ph2 Ovarian Cancer trial since it will answer a few important questions.

https://clinicaltrials.gov/ct2/show/NCT03042702?term=cellceutix&rank=1&flds=abcefgps&submit_fld_opt=









In Reply to 'Jhawker'
I am very excited about the poster that was presented today. AML is a very deadly and almost incurable blood disease.




To follow KarinCA, click here then click "Follow This Member" under my photo.

Be kinder than necessary, for everyone you meet is fighting some kind of battle.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News